**FOI Ref: 6383**

**Category(ies): Clinical - Drugs**

**Subject: Biologic Drugs in Dermatology and Gastroenterology**

**Date Received: 11/05/2022**

|  |  |
| --- | --- |
| **Your request:** | **Our response:** |
| I have a freedom of information request regarding the use of Biologic medicines. Could you please answer the following two questions?  |
| 1. How many patients were treated in the last 3 months by the Dermatology department (for any medical condition) with the following biologic drugs:
* Adalimumab - Humira
* Adalimumab Biosimilar
* Apremilast
* Bimekizumab
* Brodalumab
* Certolizumab
* Dimethyl fumarate
* Etanercept - Enbrel
* Etanercept Biosimilar
* Guselkumab
* Infliximab - Remicade
* Infliximab Biosimilar
* Ixekizumab
* Risankizumab
* Secukinumab
* Tildrakizumab
* Ustekinumab
 | * Adalimumab – Humira - 0
* Adalimumab Biosimilar - 35
* Apremilast - 0
* Bimekizumab - 0
* Brodalumab - 2
* Certolizumab - 3
* Dimethyl fumarate - 0
* Etanercept – Enbrel - 0
* Etanercept Biosimilar - 0
* Guselkumab - 32
* Infliximab – Remicade - 0
* Infliximab Biosimilar - 0
* Ixekizumab - 5
* Risankizumab - 8
* Secukinumab - 26
* Tildrakizumab - 0
* Ustekinumab - 33
 |
| 1. How many patients were treated in the last 3 months by the Gastroenterology department (for any medical condition) with the following biologic drugs:
* Adalimumab - Humira
* Adalimumab Biosimilar
* Filgotinib
* Golimumab
* Infliximab - Remicade
* Infliximab Biosimilar
* Ozanimod
* Tofacitinib
* Ustekinumab
* Vedolizumab
 | * Adalimumab – Humira - 10
* Adalimumab Biosimilar - 53
* Filgotinib - 0
* Golimumab - 0
* Infliximab – Remicade - 1
* Infliximab Biosimilar - 39
* Ozanimod - 0
* Tofacitinib - 0
* Ustekinumab - 14
* Vedolizumab - 45
 |